Menu Search
Equities

Genmab A/S

GMAB:CPH

Genmab A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)1,447.50
  • Today's Change2.50 / 0.17%
  • Shares traded88.68k
  • 1 Year change-32.49%
  • Beta1.1515
Data delayed at least 15 minutes, as of Nov 21 2024 16:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in DKKIncome statement in DKKView more

Year on year Genmab A/S had net income fall -20.18% from 5.45bn to 4.35bn despite a 13.57% increase in revenues from 14.51bn to 16.47bn. An increase in the selling, general and administrative costs as a percentage of sales from 18.19% to 19.74% was a component in the falling net income despite rising revenues.
Gross margin96.08%
Net profit margin23.47%
Operating margin31.44%
Return on assets12.39%
Return on equity14.72%
Return on investment13.76%
More ▼

Cash flow in DKKView more

In 2023, Genmab A/S increased its cash reserves by 50.28%, or 4.97bn. The company earned 7.38bn from its operations for a Cash Flow Margin of 44.80%. In addition the company used 1.28bn on investing activities and also paid 606.00m in financing cash flows.
Cash flow per share45.64
Price/Cash flow per share32.18
Book value per share502.60
Tangible book value per share283.58
More ▼

Balance sheet in DKKView more

Genmab A/S has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 14.87bn.
Current ratio5.17
Quick ratio5.15
Total debt/total equity0.0309
Total debt/total capital0.03
More ▼

Growth rates in DKK

Year on year, growth in earnings per share excluding extraordinary items dropped -20.06%. Additionally, five year annualized earnings per share growth ranks highest in its industry.
EPS growth(5 years)22.71
EPS (TTM) vs
TTM 1 year ago		12.29
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.